Sugi Predict

Sugi Predict / Compounds / SCHEMBL902334

SCHEMBL902334

SCHEMBL902334

Oc1c(Cc2ccccc2)c(C2CC2)nc2ccnn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 4/20 0.41
▸ KCNN3 Q9UGI6 2/20 0.38
▸ KCNN1 Q92952 1/20 0.38
▸ KCNN2 Q9H2S1 1/20 0.38
▸ MAPKAPK2 P49137 1/20 0.38
▸ DPP4 P27487 3/20 0.36
▸ RAD52 P43351 1/20 0.35
▸ CCNE1 P24864 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ HTR1D P28221 2/20 0.34
▸ HTR3A P46098 2/20 0.34
▸ HTR6 P50406 2/20 0.34
▸ TMEM97 Q5BJF2 2/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ HTR1B P28222 1/20 0.34
▸ MAPK8 P45983 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ MRGPRX2 Q96LB1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15274708 0.89 CCR2 (0.44) CCR2DPP4PDE10A
SCHEMBL15274707 0.87 CCR2 (0.48) CCR2KCNN3RAD52PDE10A
SCHEMBL902809 0.87 CCR2 (0.49) CCR2KCNN3KCNN1KCNN2RAD52
SCHEMBL902561 0.86 CCR2 (0.37) CCR2KCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL901602 0.86 CETP (0.42) CCR2KCNN3
SCHEMBL902483 0.85 CCR2 (0.47) CCR2KCNN3KCNN1KCNN2DPP4
SCHEMBL902501 0.85 CCR2 (0.38) CCR2KCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL902593 0.85 CCR2 (0.41) CCR2KCNN3KCNN1KCNN2DPP4
SCHEMBL902701 0.84 CCR2 (0.50) CCR2KCNN3
SCHEMBL902108 0.84 CCR2 (0.34) CCR2KCNN3KCNN1KCNN2MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 — — EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CCR2 1/4885KCNN3 4658/4885KCNN1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.